Squamous cell carcinoma of the breast
Squamous cell carcinoma of the breast
复制标题
DOI：
10.1200/jco.2004.00.9589
复制
发表时间：
2005-11-01
影响因子：
45.3
通讯作者：
Hortobagyi, GN
中科院分区：
文献类型：
--
作者：
Hennessy, BT;Krishnamurthy, S;Hortobagyi, GN
目的乳腺鳞状细胞癌是一种罕见的恶性肿瘤.在这项研究中，我们分析了33例在德克萨斯大学医学博士。安德森癌症中心（休斯顿，德克萨斯州）和通过监测、流行病学和最终结果（SEER）数据库确定的一系列137名患者进行治疗建议。检索安德森癌症中心1985年至2001年诊断为乳腺SCC的患者。所有活检材料均由专门的乳腺病理学家进行审查，该病理学家对激素受体和表皮生长因子受体（EGFR）进行免疫组织化学检查。方法：检索SEER数据库中1988 ~ 2001年诊断为乳腺癌的患者。结果：共确诊乳腺癌33例，其中2例有转移。31例局限性疾病患者的中位无复发生存期（RFS）为20个月（范围，1至108个月），5年RFS率为26%。这些患者的中位总生存期为37个月（范围为12至108个月），其中40%的患者在5年时存活。从确认复发疾病开始的中位生存期为14个月（范围，2至86个月）。肿瘤通常为激素受体和HER 2/neu阴性，尽管EGFR经常过表达。从SEER数据库的信息是一致的，我们的大部分findings.Conclusion SCC的乳腺癌是积极的，往往治疗难治性。铂盐、EGFR抑制剂和其他新型药物的作用需要探索。
Purpose Squamous cell carcinoma (SCC) of the breast is rare and generally aggressive. In this study, we analyzed 33 patients treated at The University of Texas M.D. Anderson Cancer Center (Houston, TX) and a series of 137 patients identified through the Surveillance, Epidemiology, and End Results (SEER) database to make therapy recommendations.Methods Records of The University of Texas M.D. Anderson Cancer Center were searched for patients diagnosed with breast SCC from 1985 to 2001. All biopsy material was reviewed by a dedicated breast pathologist who performed immunohistochemistry for hormone receptors and the epidermal growth factor receptor (EGFR). We searched the SEER database for patients with breast SCC diagnosed between 1988 and 2001.Results We identified 33 patients with breast SCC, of whom two patients had metastatic disease at diagnosis. The median relapse-free survival (RFS) of 31 patients with localized disease was 20 months (range, 1 to 108 months), with a 26% RFS rate at 5 years. The median overall survival in these patients was 37 months (range, 12 to 108 months), with 40% surviving at 5 years. Median survival from the time recurrent disease was recognized was 14 months (range, 2 to 86 months). Tumors were usually hormone receptor- and HER2/neu-negative, though EGFR was frequently overexpressed. Information from the SEER database was consistent with most of our findings.Conclusion SCC of the breast is aggressive and often treatment-refractory. The role of platinum salts, EGFR inhibitors, and other novel agents needs to be explored.